Association of Rituximab With Risk of Long-term Cardiovascular and Metabolic Outcomes in Patients With Pemphigus.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.5182
Abstract: Importance The association of different therapeutic approaches with long-term cardiovascular and metabolic outcomes in patients with pemphigus remains to be precisely evaluated. Objective To assess the risk of long-term cardiovascular and metabolic outcomes and all-cause… read more here.
Keywords: long term; cardiovascular metabolic; metabolic outcomes; term cardiovascular ... See more keywords
Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia.
Sign Up to like & getrecommendations! Published in 2018 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2017.0734
Abstract: Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia To the Editor We read with interest the article outlining the 2016 mSMART guidelines for the diagnosis and management of Waldenström macroglobulinemia (WM).1 We believe… read more here.
Keywords: rituximab; management waldenstr; waldenstr macroglobulinemia;
Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26306
Abstract: Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000–2015) at 12 US academic centers were assessed to identify determinants of survival across age… read more here.
Keywords: rituximab; age; analysis; rituximab era ... See more keywords
Low-dose rituximab in ITP: One and Done.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hematology"
DOI: 10.1002/ajh.26489
Abstract: Rituximab is a widely-used medication for many years, important in management of immune thrombocytopenia (ITP); however, the optimal rituximab dose remains unknown. Ni and colleagues report a clinical trial comparing 2 doses of rituximab: a… read more here.
Keywords: dose rituximab; dose; itp one; rituximab itp ... See more keywords
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non‐interventional study MabSCale
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5160
Abstract: Rituximab has become a standard treatment for non‐Hodgkin lymphoma. Clinical studies have demonstrated the efficacy of rituximab in combination with standard chemotherapies in the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma… read more here.
Keywords: lymphoma; cell lymphoma; follicular lymphoma; large cell ... See more keywords
Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30099
Abstract: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. Half of patients experience debilitating fatigue, which is currently untreatable. Previous studies have shown muscle bioenergetic abnormalities in PBC, including increased muscle acidosis with exercise… read more here.
Keywords: rituximab; improvement; pbc; fatigue ... See more keywords
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2342
Abstract: The prognosis of central nervous system (CNS) relapse of systemic non‐Hodgkin lymphoma is poor with 1‐year survival historically at 0% to 20%. Aiming to improve these results, we performed a multicenter phase 2 study in… read more here.
Keywords: rituximab; high dose; nervous system; central nervous ... See more keywords
Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2580
Abstract: Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for… read more here.
Keywords: rituximab; cll; study; fludarabine cyclophosphamide ... See more keywords
MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR)
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.75_2631
Abstract: Research Funding: Acerta Pharma. Schuster, S: Consultant Advisory Role: Novartis, Nordic Nanovector, Celgene, Merck, Gilead, Pfizer; Honoraria: Genentech, Novartis, Nordic Nanovector, Celgene, Merck, OncLive, Dava Oncology, Physician's Education Source, LLC; Research Funding: Genentech, Novartis, Nordic… read more here.
Keywords: rituximab; oncology; celgene; research funding ... See more keywords
Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-03976-w
Abstract: Dear Editor, Autoimmune hemolytic anemia (AIHA) is an autoantibodymediated anemia in which the immune system attacks and destroys red blood cells. Of patients with AIHA, 70–80% are classified as having warm AIHA (wAIHA) according to… read more here.
Keywords: rituximab; anemia; autoimmune hemolytic; response ... See more keywords
Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Hematology"
DOI: 10.1007/s00277-020-04267-0
Abstract: Although treatment outcomes for diffuse large B cell lymphoma (DLBCL) have improved with the introduction of rituximab, approximately half of patients experience relapsed/refractory (r/r) disease. Furthermore, no standard salvage therapy has yet been established to… read more here.
Keywords: relapsed refractory; rituximab; treatment; large cell ... See more keywords